

Covid-19: Medicines Criticality Group Department of Health, Miesian Plaza, Actions – Friday, 3rd April 2020

No	Action Detail	Owner	By When	Latest Update	Status
1	Monitoring of medicines used in Irish hospitals that may be used to treat Covid 19, to treat secondary infections and as supportive treatments	AHDMP & PCRS	10/03/20	In relation to ICU drugs, interrogating total quantities and rate of bed increase required. Do not expect shortages. Wholesalers have seen increase in demand for certain critical drugs in RPBs- most likely associated with LTCF- HPRA to follow up Wholesalers to send information on movement of critical goods to AHDMP twice weekly on a twice weekly basis initially	Open
2	MAHs to be contacted re availability of investigational therapeutics	AHDMP & PCRS	Ongoing	Mechanism of supply to clinical trials to be considered further	Open
3	HPRA to provide update on status of questionnaire to MAHs	HPRA	Ongoing	No significant issues currently. On the whole, general supply looks ok	Open
4	Securing ICU EMP supplies,	AHDMP	31/03	AHDMP to work on identifying alternative sources. Neuromuscular blockers- alternate supplies sourced but need to ensure use of full range of	Open



Available and suitable therapeutic agents.
Ald the process of
Neuromuscular blocking agents — increased global demand and limited availabili Risk Mitigation Strategy Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to Michael Power to be asked to communicate via Critical Care Programme. [RISK MITIGATION OUTLINED BELOW] Action Owner Risk State Prescribers Medium Critical Care Programme and Prescribers Medium AHDMP Medium
Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Short ages with Walter and suppliers to approve Support prescribers Support
Action Owner Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
Neuromuscular blocking agents — increased global demand and limited availabili Risk Mitigation Strategy Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured AHDMP Medium Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Support prescriberal with the class AHDMP Medium M
Veuromuscular blocking agents — increased global demand and limited availabili Risk Mitigation Strategy Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
Veuromuscular blocking agents — increased global demand and limited availabili Risk Mitigation Strategy Action Owner Risk State
Veuromuscular blocking agents – increased global demand and limited availabili Risk Mitigation Strategy Action Owner Risk State
Neuromuscular blocking agents — increased global demand and limited availabili Risk Mitigation Strategy Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
Neuromuscular blocking agents — increased global demand and limited availabili Risk Mitigation Strategy Action Owner Risk State
Neuromuscular blocking agents — increased global demand and limited availabili Risk Mitigation Strategy Action Owner Risk State Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured AHDMP Medium Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply AHDMP/HPRA Medium Escalation of European wide supply chain vulnerability to
Risk Mitigation Strategy Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
Risk Mitigation Strategy Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
Support prescribing of the therapeutic class, not just one moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
moiety within the class Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
unlicensed drugs to ensure additional stocks are secured AHDMP Medium Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply AHDMP/HPRA Medium Escalation of European wide supply chain vulnerability to
Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to
AHDMP to identify early disruptions to supply Escalation of European wide supply chain vulnerability to Medium
Escalation of European wide supply chain vulnerability to
EU Commission DOH Medium
· · · · · · · · · · · · · · · · · · ·
5 HSE Modelling data Department of Ongoing Department of Open
to be shared with Health Health
group when available further engagement
With modeling
group to inform ICU
requirements
6 PCRS to update PCRS & Ongoing PCRS mechanisms in Open
Group on mechanism AHDMP place and
to limit de novo
patients on claims under review
hydroxychloroquine
for antiviral purposes
7 MAH to be asked to AHDMP 07/04 Open
issue communication
to reassure patient
groups re HCQ
supplies
8 Azithromycin supplies AMRIC/ PCRS Enough stock based Open
and appropriate on normal usage.
MAHs asked to bring
usage forward orders.
M.P. drafting
prescribing guidance
to issue from HSE



_	T	T	1	T	
				MP to contact Sexual	
				Health Service	
				clinical leads	
9	Paracetamol supplies	All		Only suppositories	Open
				affected by short	
				terms supply delays.	
				Stocks to be released	
1.5				soon.	
10	Parallel exporting	HPRA		Wholesalers have confirmed not	Open
				supplying commercial	
				accounts.	
				Joint	
				communications to	
				issue from PSI and	
				HPRA reminding RPB	
				WDA holders of their	
				obligations.	
				Exporters following	
				normal rules-	
				continue to be	
				monitored.	
11	Immunocompromised	HSE National		MP to update	Open
	patients	Quality		immunosuppressant advice re cocooning to	
		Improvement		be fed into EAG	
12	Circulation list for		07/04		Open
'-		Irich Drican	01/04		Open
	Prison Service	Irish Prison			
	clinicians to be	Service			
	provided to AHDMP				
13	Group to review	DoH / HPRA	Ongoing	Department of	Open
	impact of comms as			Health to reconvene	
	regards perceived pull			comms group to	
	on supply chains and			update messaging.	
				Damantonant	
	changes in messaging			Department of Health- Lines to take,	
				formulated in	
				response to CION	
				statement to be,	
				agreed w/ industry	
				for weekend	
14	If hospital treatments	AHDMP &	Ongoing		Open
	move into	PCRS			- P
		r CN3			
	community, DoH to				
	be informed for				
	eligibility				
	considerations				
15	Establishment of a	Department of	31/03	Paused while parallel	Open
			,		
	stakeholder forum to	Health / PCI		work is progressed	
	stakeholder forum, to	Health / PSI		work is progressed	



	operate outside Subgroup meetings			
16	Clinical trials governance	DoH	Department of Health to highlight the need for CT governance to DoH colleagues.	Open